We conducted an open-labeled study to determine whether sumatriptan is more cost-effective than other therapies used to treat migraine headache. We contacted by phone 220 sumatriptan users enrolled in QualMed, a health maintenance organization (HMO) in Spokane, Washington. Of these, 203 met the inclusion criteria and 164 (81%) completed our telephone survey. The main outcome measures were healt...

5-Hydroxytryptamine (5-HT; serotonin) has been implicated in the perception of exercise-induced fatigue. Sumatriptan is a selective 5-HT(1B/D) receptor agonist which does not cross the blood-brain barrier. The aim of the present study was to determine the effect of sumatriptan on exercise capacity. Ten healthy male subjects (mean age 28.4+/-10.8 years) performed a maximal treadmill exercise tes...

10.2217/14750708.2.3.349 © 2 part of The introduction of the 5-HT1B/1D agonist sumatriptan in 1991 marked a significant advance in the management of migraine. Sumatriptan was the first migraine pharmacotherapy designed to selectively target the neurovascular origin of migraine pain. Sumatriptan was introduced in several formulations – injection, nasal spray, conventional tablet or suppository. ...

OBJECTIVES To investigate whether acupuncture is superior to placebo and equivalent to sumatriptan for the early treatment of an acute migraine attack. DESIGN Randomized, partly double-blind (sumatriptan versus placebo) trial. SETTING Two hospitals in Germany (one specialized in traditional Chinese medicine and one in the treatment of headache). SUBJECTS A total of 179 migraineurs experie...

OBJECTIVE To evaluate the impact of sumatriptan succinate injection compared with placebo on productivity loss during a migraine attack in the workplace. DESIGN Randomized, double-blind, placebo-controlled, parallel-group clinical trial. SETTING Fifteen clinical centers in the United States. PATIENTS One hundred thirty-five patients 18 years and older diagnosed as having migraine accordin...

OBJECTIVES To investigate the efficacy of a second subcutaneous dose of 6 mg sumatriptan in the treatment of recurrence of headache after successful treatment of a migraine attack with an initial 6 mg dose. METHODS In a prospective, randomised, placebo controlled, double blind, parallel group study, 803 patients were treated for one to three migraine attacks with severe or moderate headache w...

lithium is a drug used for the treatment of bipolar disorder. it has several mechanisms of action, and recently it is shown that lithium can antagonize the 5-ht1b/1d serotonin receptors. sumatriptan is a 5-ht1b/1d receptor agonist used for the treatment of cluster headaches and migraine which might cause memory impairment as a potential side effect. in this study, effects of lithium on sumatrip...

Sumatriptan is a novel and highly effective drug against migraine and cluster headache attacks. The drug is known to exert its effect through the modulation of serotonin (5-HT)mediated neurotransmission. 5-HT1B receptors in rats and 5-HT1D receptors in humans have been thought to be likely targets of sumatriptan. In the present study the effect of varying dose and duration of sumatriptan on the...

BACKGROUND The 5-HT1 agonist sumatriptan, used in the treatment of migraine, can cause chest pain. AIM To investigate the effect of a therapeutic dose of sumatriptan (6 mg s.c.) on oesophageal motility. METHODS In 16 normal healthy subjects aged 19-32 years (9 males), the manometric response of the lower oesophageal sphincter (sleeve sensor), oesophageal body (four sites), stomach and phary...

Background: Sodium valproate (SV) has been approved for migraine prophylaxis and its intravenous form is used to treat acute migraine attacks. We compared the efficacy and safety of intravenous SV and subcutaneous Sumatriptan in managing acute migraine attacks. Methods: This double-blind randomized clinical trial divided 90 patients into two groups: one group received 400 mg of intravenous SV a...